主权项 |
1. An aqueous parenteral pharmaceutical composition comprising an insulinotropic peptide, a pharmaceutically acceptable osmotic agent, a pharmaceutically acceptable preservative, a pharmaceutically acceptable dissolution enhancer, and a pharmaceutically acceptable buffer salt solution, wherein:
the aqueous parenteral pharmaceutical composition has a pH of 3.0 to 5.0; the insulinotropic peptide has a concentration of 0.1 mg/mL to 20 mg/mL; the insulinotropic peptide is GLP-1, Exendin-4, a GLP-1 analogue, an Exendin-4 analogue, a GLP-1 derivative or an Exendin-4 derivative; GLP-1 and the GLP-1 analogues have a sequence as follows:(SEQ ID NO: 1)6 10 20 30 37X6HX8EGTFTSD VSSYLEX22QAA X26EFIAWLVX34G X36X37 wherein, X6 is R or a deletion;X8 is A, G or V;X22 is G or E;X26 is K, R, Q or N;X34 is K, R, Q or N;X36 is R, R—NH2, K or K—NH2;X37 is G or a deletion; and Exendin-4 and the Exendin-4 analogue have a sequence as follows:(SEQ ID NO: 2)X1X2X3GTX6X7X8X9X10 SKQX14EEEAVX20 LX22X23X24X25LKNGGX31X32X33X34X35X36X37X38X39 wherein, X1 is H, R or Y; X2 is S, G, A or T; X3 is D or E; X6 is F or Y; X7 is T, Y or S; X8 is S or Y; X9 is D or E; X10 is L or I; X14 is L, I, V or M; X20 is R or K; X22 is F or Y; X23 is I, V, L or M; X24 is E or D; X25 is W, For Y; X31 is P or a deletion; X32 is S or a deletion; X33 is S or a deletion; X34 is G or a deletion; X35 is A or a deletion; X36 is P or a deletion; X37 is P or a deletion; X38 is P or a deletion; and X39 is S, R or a deletion. |